611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
1 in 4 U.S. Seniors With Cancer Has Had It BeforeStool-Based Protein Combos Can Improve CRC ScreeningNAFLD Linked to Increased Cancer Incidence RateCancer Survivors Can Develop PTSD, TooDrug Combo Doesn't Lengthen Glioblastoma SurvivalHealth Tip: Talking With Your Child's Cancer-Care TeamER- Breast CA Risk Up for African-Americans With T2DMHow to Do a Skin Cancer Body CheckStudy Untangles Disparity in Colon Cancer Survival RatesDiabetes May Be Driving High Rates of Breast Cancer in Black WomenOral Chemotherapy Parity Laws Offer Some Financial ProtectionHealth Tip: Recognize Symptoms of Oral CancerBreast Cancer Recurrences Steady After Therapy CessationLow-Fat Diet May Cut Pancreatic Cancer Risk for Overweight Older WomenKnow the Signs of Ovarian Cancer and Your RisksHealth Tip: Accept Help if Your Child Has CancerAverage Cost of Care in Year After Ovarian Cancer Surgery ~$100KRisk of Breast Cancer's Return Can Linger for DecadesASCO Issues Statement Regarding Alcohol and CancerEven Light Drinking May Raise Your Cancer RiskWaiting Even a Month to Remove Melanoma Can Be DeadlyIUD May Lower Cervical Cancer RiskYoga May Give Lung Cancer Patients, Caregivers a BoostFiber Tied to Lower Mortality in Those With Colorectal CancerIncidence of Early-Stage Breast CA, CRC Up With ACA AdoptionZelboraf Approved for Rare Blood CancerWhy Many Breast Cancer Patients Short-Circuit Their TreatmentCould a Common Blood Thinner Lower Cancer Risk?Are You Sure That's What the Doctor Said About Your Leukemia?Patients' Gut Bugs May Play Role in Cancer CareEven Advanced Breast Cancer Patients Gain From ExerciseFiber-Rich Diet Boosts Survival From Colon CancerDo Rising Cancer Drug Prices Warrant Regulation?Liposuction May Ease Limb Swelling in Cancer PatientsAre Some Heartburn Meds Tied to Stomach Cancer?Speed Up the 'Cancer Moonshot,' Doctors UrgeInternists Key to Identifying Need for Genetic Counseling for CancerCalquence Approved for Mantle Cell LymphomaShould Colon Cancer Screening Start at 45, not 50?Multidisciplinary Model Cuts Treatment Delay in Head, Neck CA70-Gene Signature Impacts Treatment Decisions in Breast CAGastric Cancer Incidence Down, Survival UpGene Therapy May Fight Brain Cancer's ReturnHealth Tip: Being a Cancer CaregiverMany High-Risk Women Skip MRI Breast Cancer ScreeningsSurvival Odds Improving for Lung Cancer PatientsJoan Lunden's Breast Cancer Journey: 'You Feel So Vulnerable'Mechanism ID'd for Chemo-Related Peripheral NeuropathySwedish Massage May Reduce Cancer-Related FatigueRamucirumab Shows Promise in Care of Advanced Gastric Cancer
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Chemo Drug May Buy Time for Those With Bile Duct Cancer


HealthDay News
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds.

People with bile duct cancer who received the medication lived for an average of about 17 months longer than those who didn't take it, the researchers found. Based on the findings, the study authors suggested that Xeloda should be given routinely to patients with this disease.

Bile duct cancer -- which occurs in an area that connects the liver, gallbladder and the small intestine -- is rare and aggressive. It affects an estimated 8,000 people in the United States each year, according to the American Cancer Society.

A statement from Cancer Research UK, which funded the new study, said it's difficult to study treatments for bile duct cancer because so few patients are available to take part in clinical trials.

For the study, researchers gave capecitabine (Xeloda) to about half of 450 bile duct cancer patients who underwent surgery. The other half underwent surgery but didn't get the drug.

The average survival after surgery for those who took the drug was 53 months compared to 36 months for those who only had surgery, the findings showed.

"While rare, bile duct cancer is difficult to treat and until recently there has been very little progress in treating the disease," said lead researcher John Primrose, of the University of Southampton in the United Kingdom.

"Our results clearly show that patients who have surgery should be given capecitabine, as a result of which more will survive and with few side effects," he said in a Cancer Research UK news release.

The findings are to be presented at the American Society of Clinical Oncology's annual meeting in Chicago in June. Research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.

More information

For more about bile duct cancer, visit the American Cancer Society.